Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Exclusion Criteria

• •1. Hypersensitivity to Camrelizumab, pyrotinib and study chemotherapy agents and/or to any components.
• •2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\], OX 40, Cluster of Differentiation 137 \[CD137\]).
• •3. Has an active autoimmune disease that has required systemic treatment in past 2 years.
• •4. Has a known history of Human Immunodeficiency Virus (HIV) or active hepatitis B and C virus infection.
• •5. Has had major surgery within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment.
• •6. Subjects who can not interrupt the using of the drugs that may cause QT prolongation during study.
• •7. Evidence or history of coagulation disorders such as a grade ≥ 3 (CTC-AE) bleeding event.
• •8. Known history of psychotropic substance abuse or drug use.